Author Acknowledgments

RAPS and the lead editors, Jocelyn Jennings and Bill Sietsema, thank the following subject matter experts for sharing their experience and knowledge by volunteering their time to contribute to this first edition of *Regulation of Regenerative Medicines: A Global Perspective*.

**Dylan Bechtle, MS**  
Regulatory Policy Manager  
Genentech  
US  
Chapters 5 and 17

**Bridget Bulwer**  
Head of Regulatory  
Glycostem Therapeutics  
Netherlands  
Chapter 7

**Orin Chisholm, PhD, SFHEA, FRAPS**  
Academic Lead, Pharmaceutical and Medical Device Development Programs  
Sydney Pharmacy School  
The University of Sydney  
Australia  
Chapter 15

**Stefanie Fasshauer, MBA**  
Regional Regulatory Lead APAC  
PharmaLex  
Hong Kong  
Chapter 16

**Grant S. Griffin, DRSc, RAC**  
Director of Regulatory Affairs  
TRACT Therapeutics, Inc.  
US  
Chapter 2

**Karen M. Hauda, MS, JD**  
Senior Director  
Novo Nordisk  
US  
Chapter 2

**Mo Heidarani, PhD**  
Head of Regulatory and Translational Strategy  
GC Therapeutics  
US  
Chapters 7 and 8

**Anette Hjelmsmark, MSc**  
Senior Regulatory Intelligence Manager  
Novo Nordisk  
Denmark  
Chapter 14

**Rasika Kalameghan, PhD**  
Executive Director and Head, US Regulatory Policy  
Genentech  
US  
Chapter 17

**Janet Lynch Lambert**  
Chief Executive Officer  
Alliance for Regenerative Medicine  
Foreword

**David Litwack, PhD**  
Senior Director, Scientific Strategy and Communications  
Prevail Therapeutics (a wholly-owned subsidiary of Eli Lilly and Company)  
Chapter 3
Yingying Liu MSc
Associate Director
CSL Behring
Switzerland
Chapter 14

Murphy Mao, MSc
Senior Regulatory Affair Manager
CSL Behring
China
Chapter 14

Snehal Naik, PhD
Regulatory Policy and Strategy Leader
Spark Therapeutics, Inc.
US
Chapters 5 and 17

Christiane Niederlaender, PhD
Vice President, Regulatory Consulting
Parexel
UK
Chapter 11

Brett Snyder, RAC
Regulatory Affairs Manager
US
Chapter 13

Rajesh L. Thangapazham, PhD, RAC
Executive Director, Regulatory Affairs
Aruvant Sciences
US
Chapter 6

Kristin Van Goor, PhD
Senior Director
Vertex Pharmaceuticals
US
Chapters 5 and 17

Darin J. Weber, PhD
Senior Vice President Regulatory Development
ProKidney
US
Chapter 7

Stephen Westover, RAC
Associate Director, RA CMC
Athersys
US
Chapters 2 and 10

Marites T. Woon, PhD
Senior Consultant, Regulatory Affairs
Parexel
US
Chapter 6

Linxi Wu, PhD
Regulatory Project Manager
Novo Nordisk
China
Chapter 14

Tomoki Yokoyama, MSc
Regulatory CMC Specialist
CSL Behring K.K.
Japan
Chapter 13

Aileen J. Zhou, MSc, PhD
Senior Manager, Regulatory Affairs
CCRM
Canada
Chapter 12

Andrea Zobel, PhD
Senior Director Personalized Supply Chain
AmerisourceBergen World Courier
Germany
Chapter 9

RAPS also recognizes the lead editors for their strategic vision, countless hours, and unwavering commitment to this book.

Jocelyn Jennings, MS, RAC (US, Drugs, Devices)
VP, Regulatory Affairs and Quality Assurance
Mycovia Pharmaceuticals, Inc.
US
Introduction, Chapter 4

William Sietsema, PhD
Vice President, Global Regulatory Affairs
Caladrius Biosciences
US
Preface, Chapter 10